$CDTX
Cidara Therapeutics, Inc.

2016 Q1 Form 10-K Financial Statement

#000156459016015007 Filed on March 18, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $0.00 $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $2.700M $8.840M $1.180M
YoY Change 50.0% 167.07% 1866.67%
% of Gross Profit
Research & Development $7.189M $23.48M $3.470M
YoY Change 45.67% 249.85% 1408.7%
% of Gross Profit
Depreciation & Amortization $180.0K $460.0K $90.00K
YoY Change 100.0% 155.56%
% of Gross Profit
Operating Expenses $9.885M $32.31M $4.649M
YoY Change 46.84% 178.01% 1503.1%
Operating Profit -$9.885M -$32.31M -$4.649M
YoY Change 46.84% 178.01% 1503.1%
Interest Expense $96.00K $120.0K $0.00
YoY Change -2020.0% -236.36% -100.0%
% of Operating Profit
Other Income/Expense, Net $96.00K $120.0K
YoY Change -2020.0% -144.28%
Pretax Income -$9.790M -$32.19M -$4.650M
YoY Change 45.25% 170.73% 1062.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.789M -$32.19M -$4.649M
YoY Change 45.3% 170.67% 1062.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$708.9K -$2.334M -$344.7K
COMMON SHARES
Basic Shares Outstanding 13.82M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.70M $107.5M $22.80M
YoY Change 66.44% 371.49% 11300.0%
Cash & Equivalents $51.70M $62.60M $22.80M
Short-Term Investments $45.00M $45.00M
Other Short-Term Assets $900.0K $700.0K $200.0K
YoY Change 200.0% 250.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $97.50M $108.2M $23.01M
YoY Change 66.95% 370.43% 11406.5%
LONG-TERM ASSETS
Property, Plant & Equipment $1.600M $1.700M $863.0K
YoY Change 96.56% 88.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $474.0K
YoY Change -93.62% -80.0%
Total Long-Term Assets $1.700M $1.800M $1.337M
YoY Change -28.6% 28.57%
TOTAL ASSETS
Total Short-Term Assets $97.50M $108.2M $23.01M
Total Long-Term Assets $1.700M $1.800M $1.337M
Total Assets $99.20M $110.0M $24.35M
YoY Change 63.2% 350.82% 12075.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.300M $3.100M $1.177M
YoY Change -23.35% 158.33%
Accrued Expenses $2.800M $2.900M $1.622M
YoY Change 60.92% 45.0% 1522.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.100M $6.000M $3.213M
YoY Change 7.64% 87.5% 3113.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $100.0K $100.0K $34.00K
YoY Change 222.58%
Total Long-Term Liabilities $100.0K $100.0K $34.00K
YoY Change 222.58% -97.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.100M $6.000M $3.213M
Total Long-Term Liabilities $100.0K $100.0K $34.00K
Total Liabilities $4.100M $6.100M $3.247M
YoY Change 6.77% 90.63% 102.94%
SHAREHOLDERS EQUITY
Retained Earnings -$13.30M
YoY Change
Common Stock $1.862M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.10M $103.9M -$11.45M
YoY Change
Total Liabilities & Shareholders Equity $99.20M $110.0M $24.35M
YoY Change 63.2% 350.82% 12075.0%

Cashflow Statement

Concept 2016 Q1 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$9.789M -$32.19M -$4.649M
YoY Change 45.3% 170.67% 1062.25%
Depreciation, Depletion And Amortization $180.0K $460.0K $90.00K
YoY Change 100.0% 155.56%
Cash From Operating Activities -$10.89M -$25.96M -$3.170M
YoY Change 80.0% 236.71% 712.82%
INVESTING ACTIVITIES
Capital Expenditures $54.00K $1.170M -$140.0K
YoY Change 74.19% 18.06%
Acquisitions
YoY Change
Other Investing Activities $40.00K -$44.92M
YoY Change
Cash From Investing Activities -$10.00K -$46.09M -$140.0K
YoY Change -66.67% 4555.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $69.51M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 111.8M 540.0K
YoY Change -99.9% 257.11%
NET CHANGE
Cash From Operating Activities -10.89M -25.96M -3.170M
Cash From Investing Activities -10.00K -46.09M -140.0K
Cash From Financing Activities 40.00K 111.8M 540.0K
Net Change In Cash -10.86M 39.76M -2.770M
YoY Change -130.74% 75.85% 610.26%
FREE CASH FLOW
Cash From Operating Activities -$10.89M -$25.96M -$3.170M
Capital Expenditures $54.00K $1.170M -$140.0K
Free Cash Flow -$10.94M -$27.13M -$3.030M
YoY Change 79.97% 211.8% 676.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
5331000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
482000
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13822747
CY2015Q2 dei Entity Public Float
EntityPublicFloat
95200000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62562000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22796000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
44952000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
704000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
217000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
108218000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
23013000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1464000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
120000
CY2013 cdtx Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-167000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
819868
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.51
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.15
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9920382
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
323689
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1415000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1622000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1684000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
863000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
72000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
474000
CY2015Q4 us-gaap Assets
Assets
109974000
CY2014Q4 us-gaap Assets
Assets
24350000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3095000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1177000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5974000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3213000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
88000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2015Q4 us-gaap Liabilities
Liabilities
6062000
CY2014Q4 us-gaap Liabilities
Liabilities
3247000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149416000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1859000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45497000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13304000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
103912000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-11445000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109974000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24350000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
185000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13942520
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1494506
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13786285
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1132738
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6710000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
810000
CY2014 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1607000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
272000
CY2013 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1344000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.25
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-65000
CY2014 cdtx Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-183000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
120000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-32193000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-11894000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32201000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11894000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1398000
CY2014 cdtx Stock Issued During Period Value For In Process Research And Development
StockIssuedDuringPeriodValueForInProcessResearchAndDevelopment
1607000
CY2014 cdtx Vested Restricted Shares Previously Issued As Performance Based Compensation In Value
VestedRestrictedSharesPreviouslyIssuedAsPerformanceBasedCompensationInValue
5000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
232000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69271000
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3033000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
225000
CY2015 cdtx Vested Restricted Shares Previously Issued As Performance Based Compensation In Value
VestedRestrictedSharesPreviouslyIssuedAsPerformanceBasedCompensationInValue
499000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-8000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
461000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
179000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3033000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
232000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
11000
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
66000
CY2013 us-gaap Paid In Kind Interest
PaidInKindInterest
66000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
42000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
22000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
23000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
29000
CY2015 us-gaap Straight Line Rent
StraightLineRent
-54000
CY2014 us-gaap Straight Line Rent
StraightLineRent
-34000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
487000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
204000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2143000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1746000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
36000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1050000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
414000
CY2014 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
96000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-25959000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7710000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1048000
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54918000
CY2015 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-10000000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1170000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
991000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-46088000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-991000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69505000
CY2014 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
233000
CY2015 cdtx Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plans
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlans
387000
CY2014 cdtx Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plans
ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlans
749000
CY2014 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
930000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1232000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
111813000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
31312000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1232000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39766000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22611000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
184000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
113000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
51000
CY2015 cdtx Deferred Initial Public Offering Costs
DeferredInitialPublicOfferingCosts
234000
CY2014 cdtx Deferred Initial Public Offering Costs
DeferredInitialPublicOfferingCosts
146000
CY2015 cdtx Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
499000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
226000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;font-style:normal;">&#8212;The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s financial statements relate to estimating the fair value of the Company&#8217;s common shares used to account for share-based compensation and certain accruals, including those related to preclinical and clinical activities. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p></div>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk<font style="font-weight:normal;font-style:normal;">&#8212;The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. Periodically, the Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</font></p></div>
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
49000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18454000
CY2015Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Company’s board of directors and stockholders approved a 1-for-25.4 reverse stock split
CY2015Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.039370
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1593818
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4910508
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
44960000
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
8000
CY2015 cdtx Maturity Period Of Short Term Investments
MaturityPeriodOfShortTermInvestments
All available-for-sale securities held at December 31, 2015 will mature in less than one year.
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
0
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2321000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1042000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
637000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
179000
CY2015 cdtx Number Of Votes Entitlement For Each Share Held
NumberOfVotesEntitlementForEachShareHeld
1
CY2015 cdtx Common Stock Dividends In Arrears Or Default
CommonStockDividendsInArrearsOrDefault
0
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3033000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
232000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.81
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2200000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4700000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3451983
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4560802
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10946000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4044000
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-457000
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1821000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-672000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-62000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
341000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
132000
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
80000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
676000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
265000
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
18000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13084000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4849000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
457000
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
18000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15646000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4187000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
433000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
987000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
248000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
283000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
590000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18454000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
5331000
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
635000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1231000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
94000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
482000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
356000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
108000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
318000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
102000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
6000
CY2015Q4 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0
CY2015 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The lease expires in December 2018 with options for two individual two-year extensions.
CY2015 cdtx Number Of Operating Lease Options For Extension
NumberOfOperatingLeaseOptionsForExtension
2
CY2015 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-12-31
CY2015 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P2Y
CY2015 cdtx Increase In Base Rent Annual
IncreaseInBaseRentAnnual
0.03
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
704000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
725000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
747000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2176000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
581000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
182000
CY2015 cdtx Contractual Obligation Contract Termination Notice Period
ContractualObligationContractTerminationNoticePeriod
P30D
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
6732000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
6446000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
9207000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
9928000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
32000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000
CY2015Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
60000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6737000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6414000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-9174000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-9868000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.92
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1138911
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10957150
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13674568
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13731519
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
559000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
3095000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
3320000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
4649000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-124000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-707000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3219000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3319000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-4649000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.81
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.13
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
389839
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
638272
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1113439
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1126707
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.04
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.98

Files In Submission

Name View Source Status
0001564590-16-015007-index-headers.html Edgar Link pending
0001564590-16-015007-index.html Edgar Link pending
0001564590-16-015007.txt Edgar Link pending
0001564590-16-015007-xbrl.zip Edgar Link pending
cdtx-10k_20151231.htm Edgar Link pending
cdtx-20151231.xml Edgar Link completed
cdtx-20151231.xsd Edgar Link pending
cdtx-20151231_cal.xml Edgar Link unprocessable
cdtx-20151231_def.xml Edgar Link unprocessable
cdtx-20151231_lab.xml Edgar Link unprocessable
cdtx-20151231_pre.xml Edgar Link unprocessable
cdtx-ex1016_1863.htm Edgar Link pending
cdtx-ex211_1758.htm Edgar Link pending
cdtx-ex231_965.htm Edgar Link pending
cdtx-ex311_11.htm Edgar Link pending
cdtx-ex312_10.htm Edgar Link pending
cdtx-ex321_9.htm Edgar Link pending
cdtx-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016031719155745613703.jpg Edgar Link pending
g2016031719155801913704.jpg Edgar Link pending
g2016031719155803413705.jpg Edgar Link pending
g2016031719155858113706.jpg Edgar Link pending
g2016031719155859713707.jpg Edgar Link pending
g2016031719155861213708.jpg Edgar Link pending
g2016031719155862813709.jpg Edgar Link pending
g2016031719155865913710.jpg Edgar Link pending
g2016031719155889413711.jpg Edgar Link pending
g2016031719161020713712.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending